Acute Myeloid Leukemia (AML) Therapeutics Market Size, Trends And Forecasts, 2017 To 2025

Global Acute Myeloid Leukemia (AML) Therapeutics Market Size, Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025

Acute Myeloid Leukemia (AML) Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global acute myeloid leukemia (AML) therapeutics market was valued at US$ 404.3 Mn in 2016, and is expected to reach US$ 1,025.9 Mn by 2025, expanding at a CAGR of 10.9% from 2017 to 2025.

View Full Report with TOC @ http://www.acutemarketreports.com/report/acute-myeloid-leukemia-aml-therapeutics-market

Market Insights

Global acute myeloid leukemia (AML) therapeutics market will show significant market growth during forecast period due to some factors such as rising incidence of AML, higher number of unmet needs, expected launch of ideal molecules and extensive R&D activities in development of novel therapeutics. For the purpose of study AML therapeutics market is segmented on the basis of drug type such as pipeline drugs and chemotherapeutics drugs (Cytarabine, Anthracyclines, Etoposide and other). It is studied that currently, Cytarabine is preferably used in market due to its effectiveness and hence it is prime drug of chemotherapy regimens for induction therapy as well as post-remission therapy.

Newly approved drugs such as gemtuzumab ozogamicin, Vyxeos, midostaurin expected to drive significant market growth during forecast period. In the base year 2016, North America is largest regional market for AML therapeutics, United States held largest market share in North America due to increase in prevalence of AML and developed healthcare infrastructure. It is estimated that Asia Pacific will show highest market growth during forecast period due to increasing healthcare awareness, developing healthcare infrastructure and increasing incidence of AML.

View Full Report with TOC @ http://www.acutemarketreports.com/report/acute-myeloid-leukemia-aml-therapeutics-market

Market Competition Assessment:

The acute myeloid leukemia (AML) therapeutics market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Abbott Laboratories, Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical), Boehringer Ingelheim GmbH, Bristol Myers Squibb, Celegene Corporation, Cephalon Inc., Eisai Co. Ltd., Eli Lilly and Company, Genzyme Corporation (A subsidiary of Sanofi S.A.), Jazz Pharmaceuticals, Inc., Novartis AG, Pfizer Inc. and other.

Key Market Movements:

• Factors such as rising incidence of AML, extensive research and development activities, strong presence of pipeline molecules and upsurge in funding by the government for treatment are driving the growth of AML therapeutics market during forecast period.
• However, some factors such as lack of medication availability and poor diagnosis in some poor income countries may negatively impacting the growth of acute myeloid leukemia (AML) therapeutics market.

Download Free Sample Report @ http://www.acutemarketreports.com/request-free-sample/43293

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.

Contact info:

Name: Chris Paul

Designation: Global Sales Manager

Email:  sales@acutemarketreports.com

Ph:  +1-855-455-8662

Web: www.acutemarketreports.com

Showing 1 reaction

Please check your e-mail for a link to activate your account.

connect

get updates